Shilpa Medicare Ltd receives US FDA approval for Psoriatic Arthritis Drug

Shilpa Medicare Ltd has received U.S Food and Drug Administration final approval for its ANDA, Apremilast Tablets, 10 mg, 20 mg, and 30 mg for the treatment of adult patients with active psoriatic arthritis. The product is executed from a contract manufacturing site.

Apremilast Tablets, 10 mg, 20 mg, and 30 mg is a generic equivalent of reference listed drug (RLD) OTEZLA of Celgene.

According to IQVIA MAT Q4 2022 data, the US market for Apremilast Tablets, 10 mg, 20 mg, and 30 mg is approximately US $ 3.55 Billion.

Shares of Shilpa Medicare Limited was last trading in BSE at Rs. 233.20 as compared to the previous close of Rs. 237.90. The total number of shares traded during the day was 53788 in over 1178 trades.

The stock hit an intraday high of Rs. 240.35 and intraday low of 232.50. The net turnover during the day was Rs. 12782768.00.

Source : Equity Bulls

Keywords

ShilpaMedicare INE790G01031 USFDA FinalApproval ANDA ApremilastTablets PsoriaticArthritis